中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (4): 797-798.doi: 10.4103/1673-5374.353486

• 观点:神经损伤修复保护与再生 • 上一篇    下一篇

用于获得差别调节髓鞘形成的治疗剂的下一代药物连接图

  

  • 出版日期:2023-04-15 发布日期:2022-10-27

Next generation drug connectivity mapping for acquiring therapeutic agents to differentially regulate myelination

Kasum Azim, Andrea Domenico Rivera*, Arthur Morgan Butt*   

  1. Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany (Azim K)
    Institute of Biomedical and Biomolecular Sciences, School of Pharmacy and Biomedical Science, University of Portsmouth, St Michael’s Building, White Swan Road, Portsmouth, UK (Rivera AD, Butt AM) 
    Section of Human Anatomy, Department of Neuroscience, University of Padua, Padua, Italy (Rivera AD)
  • Online:2023-04-15 Published:2022-10-27
  • Contact: Andrea Domenico Rivera, PhD, andrea.rivera@unipd.it; Arthur Morgan Butt, PhD, arthur.butt@port.ac.uk.

摘要: https://orcid.org/0000-0002-5507-2103 (Andrea Domenico Rivera)
https://orcid.org/0000-0001-7579-0746 (Arthur Morgan Butt)

Abstract: The need for new therapeutic approaches: Conventional drug discovery is a lengthy and expensive process, taking decades and billions of dollars to get a drug from bench to bedside. Much of the costs incurred are at the pre-clinical stages, between drug design and synthesis to delineating the cellular “Mechanisms of Action” (MoA). Notably, there is a very high risk of failure, and only a very small proportion of therapeutic agents reach later-phase clinical trials. Accordingly, drug repositioning has become a valuable strategy aimed at fast-tracking treatments into clinical use and improving the chances of therapeutic success. A novel addition to this approach is connectivity mapping, which defines cell-specific transcriptional responses to small molecules in disease-dependent contexts. This commentary outlines how some of the latest innovations in connectivity mapping can be exploited for drug repurposing.